THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA. REMUS PHARMACEUTICALS LIMITED

Corporate Identification Number: U24232GJ2015PLC084536

Our Company was originally incorporated as 'Remus Pharmaceuticals Private Limited' as a private limited company, under the provisions of the Companies, Gujarat. Subsequently, pursuant to a special resolution passed by our Shareholders in the Extra-Ordinary General Meeting held on January 02, 2023, our Company was converted from a private limited company to public limited company and consequently, the name of our Company was changed to "Remus Pharmaceuticals Limited" and a fresh certificate of incorporation dated January 06, 2023 was issued to our Company by the Registrar of Companies, Ahmedabad. The Corporate Identification Number of our Company is U24232GJ2015PLC084536.

Registered Office: 1101 to 1103, South Tower, One 42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli bopal Road, Ahmedabad - 380054, Gujarat, India

Website: www.remuspharma.com; E-Mail: cs@remuspharma.com; Telephone No: +079- 2999 9857; Company Secretary and Compliance Officer: Ms. Deval Bakulkumar Patel

PROMOTERS OF OUR COMPANY: MR. ARPIT DEEPAKKUMAR SHAH, MS. ROMA VINODBHAI SHAH, MR. SWAPNIL JATINBHAI SHAH AND MRS. ANAR SWAPNIL SHAH

INITIAL PUBLIC ISSUE OF 388000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF REMUS PHARMACEUTICALS LIMITED ("RPL" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ [•]/- PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING TO ₹[•] LAKHS ("THE ISSUE"), OF WHICH 19500 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH FOR CASH AT A PRICE OF ₹[•]/- PER EQUITY SHARE AGGREGATING TO ₹[•] LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER TO THE ISSUE (THE "MARKET MAKER TO THE ISSUE"). MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION i.e. NET ISSUE OF 368500 EQUITY SHARE OF ₹ [•]/- PER EQUITY SHARE AGGREGATING TO ₹ [•] LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 26.34% AND 25.02%, RESPECTIVELY, OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY. THE FACE VALUE OF THE EQUITY SHARES IS ₹ 10/- EACH.

> QIB Portion: Not More than 50% of the Net Issue Retail Individual Bidders Portion: Not less than 35% of the Net Issue

Non-Institutional Bidders Portion: Not Less than 15% of the Net Issue

Price Band: ₹ 1150/- to ₹ 1229/- per Equity Share of Face Value ₹ 10/- each.

The Floor Price is 115.00 times of the Face Value and the Cap Price is 122.90 times of the Face Value. Bids can be made for a minimum of 100 Equity Shares and in multiples of 100 Equity Shares thereafter.

ASBA*

Simple, Safe, Smart way of Application-Make use of it !!!

*Applications Supported by Blocked Amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account, investors can avail the same. For details, check section on ASBA below. Mandatory in Public Issues from January 01, 2016. No cheque will be accepted

Now available in ASBA for Retail Individual Investors (RII)**

Investors are required to ensure that the bank account used for bidding is linked to their PAN. UPI - Now available in ASBA for RIIs applying through Registered Brokers, DPs & RTAs. RIIs also have the option to submit the application directly to the ASBA Bank (SCSBs) or to use the facility of linked online trading, demat and bank account.

page 246 of the RHP. The process is also available on the website of Association of Investment Bankers of India ("AIBI"), the Stock Exchanges and in the General Information Document.

*ASBA forms can be downloaded from the website National Stock Exchange of India ("NSE") and can be obtained from the list of banks that is displayed on the website of SEBI at www.sebi.gov.in. **List of banks supporting UPI is also available on the website of SEBI at www.sebi.gov.in . ICICI Bank Limited has been appointed as Sponsor Bank for the Issue, in accordance with the requirements of the SEBI circular dated November 1, 2018, as amended. For UPI related queries, investors can contact NPCI at the toll free number-18001201740 and Mail Id-ipo.upi@npci.org.in. • For the list of UPI Apps and Banks live on IPO, please refer to the link www.sebi.gov.in . For issue related grievance investors may contact: Beeline Capital Advisors Private Limited - Mr. Nikhil Shah (079 4918 5784) (mb@beelinemb.com).

Investors have to apply through the ASBA process. "ASBA has to be availed by all the investors except anchor investor. UPI may be availed by Retail Individual Investors and also please refer to the section "Issue Procedure" beginning on

Risks to Investors:

- The Company is dependent on few numbers of customers for sales. Loss of any of this large customer may affect our revenues and profitability.
- The Merchant Banker associated with the Issue has handled 12 public issues out of which 2 issue closed below issue price on listing date.
- Average cost of acquisition per Equity Share by our Promoters, Mr. Arpit Deepakkumar Shah is ₹ 0.10, Mrs. Roma Vinodbhai Shah is ₹ 0.10, Mrs. Swapnil Jatinbhai Shah is ₹ 0.06, and Mrs. Anar Swapnil Shah is ₹ 9.45 per Equity Share.
- The Issue Price at the upper end of the Price Band is ₹ 1229/- per Equity Share.
- Weighted Average Return on Net worth for period Fiscals 2022, 2021 and 2020 is 44.24% and Average Return on Net worth for the Period ended on December 31, 2022 is 37.61%.

The Issue Price will be determined by our Company in consultation with the Book Running Lead Manager on the basis of the assessment of market demand for the Equity Shares through the Book Building Process and on the basis of quantitative and Equity Qualitative factors as described below. The face value of the Equity Shares is ₹10 each and the Issue Price is 115.0 times the face value at the lower end and the Price Band and 122.9 times the face value at the higher end of the Price Band. Investors should also refer to "Business Overview", "Risk Factors", "Restated Financial Information" and "Management's Discussion and Analysis of Financial Position and Results of Operations" beginning on pages 115, 26, 189 and 191, respectively of the Red Herring Prospectus, to have an informed view before making an investment decision.

Qualitative Factors

- Experienced Promoters and Management Team
- Wide range of Products Scalable Business Model
- Strategic Location of Manufacturing Facilities

Diversified business operations and revenue base

For details of qualitative factors, please refer to the paragraph "Our Competitive Strengths" in the chapter titled "Business Overview" beginning on page no. 115 of the Red Herring Prospectus.

Quantitative Factors

Basic & Diluted Earnings Per Share (EPS):

Restated Profit After Tax attributable to Equity Shareholders Basic earnings per share (₹) =

Weighted Average Number of Equity Shares outstanding

Restated Profit After Tax attributable to Equity Shareholders Diluted earnings per share (₹) =

Weighted Average Number of Equity Shares outstanding after adjusting adjusted for the effects of all dilutive potential equity shares

Financial Year/Period	Basic and Diluted EPS (in ₹)#	Weights
Financial Year ended March 31, 2020	8.12	1
Financial Year ended March 31, 2021	10.26	2
Financial Year ended March 31, 2022	33.86	3
Weighted Average	21.70	
For the Period ended on December 31, 2022*	64.35	

#Face Value of Equity Share is ₹10.

*Not annualized Price to Earnings (P/E) ratio in relation to Issue Price of ₹ [●]:

Issue Price Price to Earnings Ratio (P/E) = Restated Earnings Per Share

Particulars	P/E at the lower end of the Price Band	P/E at the upper end of the Price Band
Based on EPS of Financial Year ended March 31, 2022	33.96	36.30
Based on Weighted Average EPS	52.99	56.64

Highest = 99.06Lowest = 21.46

Average = 54.40

Return on Net Worth: Return on Net Worth (%)=

Restated Profit After Tax attributable to Equity Shareholders Net Worth

Financial Year/Period	Return on Net Worth (%)	Weights
Financial Year ended March 31, 2020	40.17	1
Financial Year ended March 31, 2021	33.68	2
Financial Year ended March 31, 2022	52.64	3
Weighted Average	44.24	
For the Period ended on December 31, 2022*	37.61	

*Not annualized Net Asset Value per Equity Share:

Restated Net Asset Value per equity share (₹)

Restated Net Worth as at the end of the year Number of Equity Shares outstanding

283.79

130.26

503.78

Particular	Amount (in ₹)
As at March 31, 2022	64.32
For the Period ended on December 31, 2022	157.79
NAV per Equity Share after the Issue	[₹]
Issue Price per Equity Share	[₹]

Face | Current Market | EPS (7) | P/E | RoNW |

Comparison of Accounting Ratios with Peer Group Companies

the company	Consolidated	Value (₹)	Price (₹)@	Basic	Ratio	(%)	Equity Share (₹)	(₹ in Lakhs)
Remus Pharmaceuticals Limited	Standalone	10	[•]	33.86	[•]	52.64%	64.3	2471.71
Peer Group		A.S	103,000					
Trident Lifeline Limited	Standalone	10	148.50	6.92	21.46	82.66	5.97	2176.80
Vaishali Pharma Limited ^	Standalone	10	163.05	3.82	42.68	15.27	24.99	7153.68
Chandra Bhagat Pharma Limited ^	Standalone	10	105.00	1.06	99.06	2.99	35.35	9407.56

taken as per Restated Financial Statement for the Financial Year 2021-22

Current Market Price (CMP) is taken as the closing price of respective scripts as on February 22, 2023 at BSE & NSE. For our Company, Current Market Price is taken same as issue price of equity share

The Figures as at March 31, 2022 and are taken from the financial results uploaded on respective Stock

The face value of Equity Shares of our Company is ₹ 10/- per Equity Share and the Issue price is [•] times the

face value of equity share. The Issue Price of ₹ [•]/- is determined by our Company in consultation with the Book Running Lead Manager

is justified based on the above accounting ratios. For further details, please refer to the section titled "Risk Factors" and chapters titled "Business Overview" and "Restated Financial Information" beginning on page nos.

26, 115 and 189 respectively of this Red Herring Prospectus.

Operating Cash Flows (₹ in Lakhs)

2 2 2	For The Period	For the Year ended on March 31				
Particulars	Ended on December 31, 2022*	2022	2021	2020		
Revenue from Operations (₹ in Lakhs)	3,239.17	2,471.71	1,841.81	1,191.90		
Growth in Revenue from Operations (%)	-	34.20%	54.53%			
Gross Profit (₹ in Lakhs)	1708.25	1244.94	692.38	487.91		
Gross Profit Margin (%)	52.74%	50.37%	37.59%	40.94%		
EBITDA (₹ in Lakhs)	916.17	479.07	156.82	124.24		
EBITDA Margin (%)	28.28%	19.38%	8.51%	10.42%		
Profit After Tax (₹ in Lakhs)	643.9	338.57	102.58	81.16		
PAT Margin (%)	19.88%	13.70%	5.57%	6.81%		
RoE (%)	54.68%	71.44%	40.49%	50.27%		
RoCE (%)	33.20%	69.99%	41.90%	47.76%		
Net Fixed Asset Turnover (In Times)	28.30	70.54	41.24	43.46		
Net Working Capital Days	27	-21	-3	59		

532.46

Basis For Issue Price

Source: The Figure has been certified by our statutory auditors M/s. Parikh & Majmudar, Chartered Accountants vide their certificate dated March 07, 2023 vide UDIN 23040230BGWELN6842.

Revenue from Operations means the Revenue from Operations as appearing in the Restated Financial Statements.

- Growth in Revenue from Operations (%) is calculated as a percentage of Revenue from Operations of the relevant period minus Revenue from Operations of the preceding period, divided by Revenue from Operations of the preceding period.
- Gross Profit is calculated as Revenue from Operations less Cost of Materials consumed, Purchase of stock in trade goods, Changes in inventories of finished goods, work-in-progress and stock in trade.
- Gross Profit Margin (%) is calculated as Gross Profit divided by Revenue from Operations.
- EBITDA is calculated as profit for the period / year, plus tax expenses (consisting of current tax, deferred tax and current taxes relating to earlier years), finance costs and depreciation and amortization expenses.

Remus Pharmaceuticals Limited

- EBITDA Margin (%) is calculated as EBITDA divided by Revenue from Operations.
- Profit After Tax Means Profit for the period/year as appearing in the Restated Financial Statements.
- PAT Margin (%) is calculated as Profit for the year/period as a percentage of Revenue from Operations. RoE (Return on Equity) (%) is calculated as net profit after tax for the year / period divided by Average Shareholder Equity.
- RoCE (Return on Capital Employed) (%) is calculated as earnings before interest and taxes divided by capital employed.
- Capital Employed includes Equify Shares, Reserves and surplus, Long-Term Borrowing and Short-Term Borrowing. Net Fixed Asset Turnover is calculated as Net Turnover divided by Average Fixed Assets which consists of property, plant
- and equipment and capital work-in-progress. Net Working Capital Days is calculated as working capital (current assets minus current liabilities) as at the end of the
- period / year divided by revenue from operations multiplied by number of days in a period / year. Operating cash flows means net cash generated from operating activities as mentioned in the Restated Financial

Revenue split between domestic and exports Domestic Market (in Lakhs) 15.98 155.48 307.65 0.00 Export Market (in Lakhs) 3223.19 1191.90 2316.23 1534.16 0.49% 6.29% 0.00% 16.70%

For The Period

Ended on

December 31, 2022*

For the Year ended on March 31

2021

Chandra Bhagat Pharma Limited

2020

2022

OPERATIONAL KPIS OF THE COMPANY:

Particulars

Domestic Market (%) 99.51% 93.71% 83.30% 100.00% Export Market (%) Contribution to revenue from operations of top 1 / 3 / 5/ 10 customers 15.34% Top 1 20.51% 21.45% 49.60% 35.73% 46.57% 58.18% 72.37% Top 3 Top 5 53.08% 64.34% 72.92% 85.09% 73.66% Top 10 83.21% 88.92% 98.10%

Source: The Figure has been certified by our statutory auditors M/s. Parikh & Majmudar, Chartered Accountants vide their certificate dated March 07, 2023 vide UDIN 23040230BGWELN6842. COMPARISON OF FINANCIAL KPIS OF OUR COMPANY AND OUR LISTED PEERS:

While our listed peers (mentioned below), like us, operate in the Marketing and Distribution of finished formulation of pharmaceuticals drugs etc. and may have similar offerings or end use applications, our business may be different in terms of differing business models, different product verticals serviced or focus areas or different geographical

Vaishali Pharma Limited

Particulars	For the	Year ended on Ma	ided on March 31		For the Year ended on March 31			For the Year ended on March 31			For the Year ended on March 31		
	2022	2021	2020	2022	2021	2020	2022	2021	2020	2022	2021	2020	
Revenue from Operations (₹ in Lakhs)	2,471.71	1,841.81	1,191.90	2176.80	962.22	493.49	7582.08	5377.39	6008.57	9407.56	7069.53	9398.09	
Growth in Revenue from Operations (%)	34.20%	54.53%		126.23%	94.98%	24	41.00%	-10.50%		33.07%	-24.78%		
Gross Profit (₹ in Lakhs)	1244.94	692.38	487.91	753.78	291.13	128.71	1232.02	762.24	899.66	1271.73	1095.50	818.21	
Gross Profit Margin (%)	50.37%	37.59%	40.94%	34.63%	30.26%	26.08%	16.25%	14.17%	14.97%	13.52%	15.50%	8.71%	
EBITDA (₹ in Lakhs)	479.07	156.82	124.24	331.20	141.20	(11.56)	864.34	444.21	299.91	429.61	379.59	351.47	
EBITDA Margin (%)	19.38%	8,51%	10.42%	15.21%	14.67%	-2.34%	11.40%	8.26%	4.99%	4.57%	5.37%	3.74%	
Profit After Tax (₹ in Lakhs)	338.57	102.58	81.16	394.77	93.11	(99.59)	402.36	104.63	3.28	79.67	18.99	31.48	
PAT Margin (%)	13.70%	5.57%	6.81%	18,14%	9.68%	-20.18%	5.31%	1.95%	0.05%	0.85%	0.27%	0.33%	
RoE (%)	71.44%	40.49%	50.27%	303.25%	-25.95%	20.12%	16.50%	4.78%	0.15%	3.03%	0.74%	1.57%	
RoCE (%)	69.99%	41.90%	47.76%	43.01%	52.74%	-15.84%	17.38%	10.55%	6.91%	8.98%	7.38%	6.55%	
Net Fixed Asset Turnover (In Times)	70.54 Times	41.24 Times	43.46 Times	64.58 Times	31.30 Times	18.14 Times	96.11 Times	71.56 Times	72.33 Times	210.06 Times	164.69 Times	208.89 Times	
Net Working Capital Days	-21 Days	-3 Days	59 Days	52.00 Days	37.00 Days	(11.00) Days	118.00 Days	150.00 Days	127.00 Days	127.00 Days	192.00 Days	152.00 Days	
Operating Cash Flows (₹ in Lakhs)	503.78	283.79	130.26	(19,19)	(32.02)	(81.86)	131.87	201.11	321.88	1246.22	832.87	(741.30)	

Trident Lifeline Limited

Chandra Bhagat Pharma Limited Remus Pharmaceuticals Limited Vaishali Pharma Limited Trident Lifeline Limited For the Year ended on March 31 Particulars For the Year ended on March 31 For the Year ended on March 31 For the Year ended on March 31 2022 2021 2020 2022 2021 2020 2022 2021 2020 2022 2021 2020 Revenue split between domestic and exports Market

Widther		1	1	1	I	1		1		1		l
(in Lakhs)	15.97	155.48	307.65	:NA:	NA.	NA.	NA	NA NA	NA	NA	NA NA	NA.
Export Market			7		9						S	
(in Lakhs)	3223.19	2316.23	1534.16	NA	NA.	NA	NA	NA	NA	NA	NA NA	NA
Domestic		CHX00810001		3680)	7.000	0.837	5500	NEW CALL	0.000	3050.0	0.00	15000000
Market (%)	0.49%	6.29%	16.70%	NA	NA NA	NA.	NA NA	NA NA	NA NA	NA NA	NA.	NA NA
Export Market	C120000000	-1100-000	101.000.000	20000		15000	0000	1.5400.00	2000	2000	5000	The state of the s
(%)	99.51%	93.71%	83.30%	NA NA	NA NA	NA.	NA NA	NA.	NA NA	NA.	NA NA	NA.
Contribution to re	evenue from operation	ons of top 1 / 3 / 5/ 10	customers	- 4 - 45 6101 - 1		190		01,035	70000	72921	10	
Top 1	20.51%	21.45%	49.60%	NA	NA NA	NA	NA NA	NA NA	NA	NA	NA	NA NA
Top 3	46.57%	58.18%	72.37%	NA	NA NA	NA.	NA	NA.	NA	NA	NA	NA.
Top 5	64.34%	72.92%	85.09%	NA	NA	NA	NA	NA	NA	NA	NA	NA NA
Top 10	83.21%	88.92%	98.10%	NA.	NA	NA NA	NA	NA NA	NA NA	NA.	NA.	NA.

Source: The Figure has been certified by our statutory auditors M/s. Parikh & Majmudar, Chartered Accountants vide their certificate dated March 07, 2023 vide UDIN 23040230BGWELN6842. Revenue from Domestic and Export Market refers to corresponding disclosures in the Restated Financial Statements

Contribution to Revenue from Operations of top 1/3/5/10 customers means aggregate revenue from top 1/3/5/10 customers divided by total Revenue from Operations. Data of Operational KPI's of the Company's listed peers is either not available in the public domain or the basis and manner of calculation of the figures mentioned is not ascertainable and therefore, may not be an accurate company's

information not available in a comparable manner, and hence not mentioned.

For further details, please see the chapter titled "BASIS FOR ISSUE PRICE" beginning on page 85 of the RHP

BID / ISSUE PROGRAM

Comparison of Operational KPIs for the Company with that of Company's listed Peers:

BID/ISSUE OPENS ON(1): WEDNESDAY, MAY 17, 2023 BID/ISSUE CLOSES ON: FRIDAY, MAY 19, 2023

(1) Our company in consultation with the BRLM may consider participation by Anchor Investors. Anchor Investor Bidding date shall be one working day prior to the Bid/Issue opening date, in accordance with SEBI ICDR Regulations.

In case of any revisions in the Price Band, the Bid/Issue Period will be extended by at least three additional Working Days after such revision of the Price Band, subject to the Bid/Issue Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar circumstances, our Company may, for reasons to be recorded in writing, extend the Bid/Issue Period for a minimum of three Working Days, subject to the Bid/Issue Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid/Issue Period, if applicable, will be widely disseminated by notification to the Stock Exchange, by issuing a press release, and also by indicating the change on the website of the Book Running Lead Managers and the terminals of the other members of the Syndicate and by intimation to SCSBs, the Sponsor Bank, Registered Brokers, Collecting Depository Participants and Registrar and Share Transfer Agents.

This Issue is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 229 of the SEBI ICDR Regulations and in compliance with Regulation 253 of the SEBI ICDR Regulations, wherein not more than 50.00% of the Net Issue shall be available for allocation on a proportional Buyers ("QIBs") (the "QIB Portion"), provided that our Company may, in consultation with the Book Running Lead Manager, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5.00% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5.00% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15.00% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Investors and not less than 35.00% of the Net Issue shall be available for allocation to Retail Individual Investors in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Issue Price. All Bidders (except Anchor Investors) are required to participate in the Issue by mandatorily

utilizing the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA Account (as defined hereinafter) in which the corresponding Bid Amounts will be blocked by the Self Certified Syndicate Banks ("SCSBs") or under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. For details, see "Issue Procedure" on page 246 of Red Herring Prospectus. Bidders / Applicants should note that on the basis of PAN, DP ID and Client ID as provided in the Bid cum Application Form, the Bidders/Applicants may be deemed to have authorized the Depositories to provide to the Registrar to the Issue, any requested Demographic Details of the Bidders/Applicants as available on the records of the depositories. These Demographic Details may be used, among other things, for or unblocking of ASBA Account or for other correspondence(s) related to an Issue. Bidders/Applicants are advised to update any changes to their Demographic Details as available in the records of the Depository Participant to ensure accuracy of records. Any delay resulting from failure to update the Demographic Details would be at the Applicants' sole risk. Bidders /Applicants should ensure that PAN, DP ID and the Client ID are correctly filled in the Bid cum Application Form. The PAN, DP ID and Client ID provided in the Bid cum Application Form should

match with the PAN, DP ID and Client ID available in the Depository database, otherwise, the Bid cum Application Form is liable to be rejected. Bidders/Applicants should ensure that the beneficiary account provided in the Bid cum Application Form Contents of the Memorandum of Association of the Company as regards its objects: For information on the main objects and other objects of our Company, see "History and Certain Corporate Matters" on page 156 of the Red Herring Prospectus and Clause III of the Memorandum of Association of our Company. The Memorandum of Association of our Company is a material document for inspection in relation to the Issue. For further details, see the section "Material Contracts and Documents for Inspection® on page 313 of the Red Herring Prospectus.

Liability of Members of the Company: Limited by shares. AMOUNT OF SHARE CAPITAL OF THE COMPANY AND CAPITAL STRUCTURE: The Authorised share capital of the Company is ₹ 2,00,00,000 Equity Shares of ₹ 10 each. The issued, subscribed and paid-up share capital of the

Company before the Issue is ₹ 1,08,50,000 divided into 10,85,000 Equity Shares of ₹ 10 each. For details of the Capital Structure, see "Capital Structure" on the page 57 of the Red Herring Prospectus. NAMES OF THE SIGNATORIES TO THE MEMORANDUM OF ASSOCIATION OF THE COMPANY AND THE NUMBER OF EQUITY SHARES SUBSCRIBED BY THEM: Given below are the names of the signatories of the Memorandum of Association of the Company and the number of Equity Shares subscribed for by them at the time of signing of the Memorandum of Association of our Company: Mr. Arpit Deepakkumar Shah - 2500 Equity Shares, Mrs. Roma Vinodohai Shar

Siddharth Shah- 1000 Equity Shares, Mr. Swapnil Jatinbhai Shah- 1000 Equity Shares and M/s, Espee Lifesciences Private Limited-3000 Equity Shares and M/s, Espee Lifesciences Private Limited-3000 Equity Shares and M/s. Structure" on the page 57 of the Red Herring Prospectus. LISTING: The Equity Shares issued through the Red Herring Prospectus are proposed to be listed on the Emerge Platform of National Stock Exchange of India Limited. Our Company has received an in-principle approval from the National Stock Exchange of

India Limited for the listing of the Equity Shares pursuant to letter dated April 28, 2023. For the purposes of the Issue, the Designated Stock Exchange shall be Emerge Platform of National Stock Exchange of India Limited. A signed copy of the Red Herring

www.readwhere.com Lucknow